| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | -7431.91% | 35.23% |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | -725746.19% | -2783.97% |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — | -710238.40% | -2676.65% |
| Net Margin | — | — | — | — | — | — | — | — | — | — | -896491.64% | -2786.92% |
| Current Ratio | 5.53 | 14.99 | 17.61 | 21.23 | 45.18 | 2.73 | 10.83 | 3.96 | 6.45 | 3.11 | 1.72 | 4.10 |
| Quick Ratio | 5.53 | 14.99 | 17.61 | 21.23 | 45.18 | 2.73 | 10.83 | 3.96 | 6.45 | 3.11 | 1.72 | 4.09 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -88.35% | -35.68% | -33.06% | -22.85% | -14.92% | -65.62% | -131.04% | -129.53% | -117.06% | -205.64% | -421.20% | -154.32% |
| ROA | -73.03% | -33.36% | -31.27% | -21.82% | -14.59% | -41.62% | -118.98% | -97.31% | -99.49% | -153.68% | -252.43% | -124.60% |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | 0.00 | 0.04 |
| Book Value / Share | 4.57 | 0.57 | 0.72 | 0.93 | 1.18 | — | — | — | — | — | 0.13 | 0.40 |
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods primarily for the treatment of breast cancer and other breast conditions. Its lead candidate, Endoxifen, targets these areas to address unmet medical needs in oncology. The company also pursues proprietary medicines in oncology more broadly, focusing on innovative approaches to improve patient outcomes. Atossa Therapeutics Inc. operates in the pharmaceutical sector, emphasizing drug development for breast-related disorders through clinical programs. Founded in 2008 and headquartered in Seattle, Washington, it advances its pipeline through research and clinical trials, contributing to advancements in breast cancer therapies within the biopharmaceutical market.